Last reviewed · How we verify

NCT04792892: ANCAII

ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer

Recruiting now Last updated 8 December 2023
What this trial tests

trial testing Questionnaires in Anal Cancer in 600 participants. Currently enrolling.

Timeline
1 August 2021
Primary endpoint
1 April 2025
1 April 2035

Quick facts

Lead sponsorSahlgrenska University Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment600
Start date1 August 2021
Primary completion1 April 2025
Estimated completion1 April 2035
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Sahlgrenska University Hospital

Who can join

18 and older, any sex, with Anal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anal cancer is a rare disease, but the incidence is rising. About 200 patients will get this type of cancer yearly in Sweden. Curative treatment includes chemotherapy and radiotherapy. The prognosis is good, but some patients will have recurrent or persistent disease after concluded chemo-radiotherapy and will then be offered salvage surgery. Some patients develop distant metastases that can be treated with good results. The aim of this study is to identify and describe functional outcome in patients diagnosed with anal cancer. We will study patients from diagnosis, try to identify early toxicity to treatment and then identify long-term morbidity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Questionnaires

Trials testing the same drug.

Other recruiting trials for Anal Cancer

Currently open trials in the same condition.

Other Sahlgrenska University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04792892.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing